nach oben

Erschienen in:

23.04.2020 | Health Services Research and Global Oncology

Peritumoral Lymphatic Vessels Associated with Resistance to Neoadjuvant Chemotherapy and Unfavorable Survival in Esophageal Cancer

verfasst von: Takeo Hara, MD, PhD, Tomoki Makino, MD, PhD, Makoto Yamasaki, MD, PhD, Koji Tanaka, MD, PhD, Kotaro Yamashita, MD, PhD, Yuya Nogi, MD, Takuro Saito, MD, PhD, Tsuyoshi Takahashi, MD, PhD, Yukinori Kurokawa, MD, PhD, Mitsuaki Tatsumi, MD, PhD, Kiyokazu Nakajima, MD, PhD, Eiichi Morii, MD, PhD, Hidetoshi Eguchi, MD, PhD, Yuichiro Doki, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Peri- or intra-tumor lymphangiogenesis is induced in several types of cancer. However, the significance of peritumoral lymphatic vessels (LVs) in esophageal cancer (EC) remains to be clarified.

Methods

This study included 162 eligible EC patients with or without neoadjuvant chemotherapy (NAC). The numbers of non-tumoral and peritumoral LVs were counted in resected specimens based on podoplanin immunostaining. The association between peritumoral LV number and clinicopathologic parameters, including tumor heterogeneity as measured by positron emission tomography, NAC response, and patient survival were analyzed.

Results

In non-NAC patients, the number of peritumoral LVs was highest in the lamina propria mucosa (LPM), followed by non-tumoral LVs in the LPM, peritumoral LVs in the submucosa (SM), and non-tumoral LVs in the SM. The patients with a low number of peritumoral LVs in the LPM versus those with a high number constituted a larger fraction of the NAC patients (67.8% vs. 50.0%; P = 0.022) and had a poorer pathologic response to NAC (grades 0–1a: 68.8% vs. 47.2%; P = 0.035), as well as greater tumor heterogeneity and worse survival (5-year overall survival: 50.6% vs. 72.8%; P = 0.0097). The number of peritumoral LVs in the LPM was identified as an independent prognostic factor with the highest hazard ratio (HR) of overall survival (HR 2.06; P = 0.0049) in the multivariate analysis.

Conclusion

For EC patients, peritumoral LVs in the LPM layer are associated with tumor heterogeneity, response to NAC, and unfavorable survival.

Nur mit Berechtigung zugänglich

Tanaka T, Matono S, Mori N, Shirouzu K, Fujita H. T1 squamous cell carcinoma of the esophagus: long-term outcomes and prognostic factors after esophagectomy. Ann Surg Oncol. 2014;21:932–8. https://doi.org/10.1245/s10434-013-3372-0.CrossRefPubMed

Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43. https://doi.org/10.1007/s10388-018-0642-8.CrossRefPubMed

Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74. https://doi.org/10.1245/s10434-011-2049-9.CrossRefPubMed

Makino T, Yamasaki M, Tanaka K, et al. Metabolic tumor volume change predicts long-term survival and histological response to preoperative chemotherapy in locally advanced esophageal cancer. Ann Surg. 2019;270:1090–5. https://doi.org/10.1097/SLA.0000000000002808.CrossRefPubMed

Saunders NA, Simpson F, Thompson EW, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med. 2012;4:675–84. https://doi.org/10.1002/emmm.201101131.CrossRefPubMedPubMedCentral

Tatsumi M, Isohashi K, Matsunaga K, et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol. 2019;24:1292–300. https://doi.org/10.1007/s10147-019-01482-2.CrossRefPubMed

Miyata H, Yamasaki M, Takahashi T, et al. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer. Br J Surg. 2013;100:1490–7. https://doi.org/10.1002/bjs.9253.CrossRefPubMed

Nakajo M, Jinguji M, Nakabeppu Y, et al. Texture analysis of (18)F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017;44:206–14. https://doi.org/10.1007/s00259-016-3506-2.CrossRefPubMed

Orlhac F, Nioche C, Soussan M, Buvat I. Understanding changes in tumor texture indices in PET: a comparison between visual assessment and index values in simulated and patient data. J Nucl Med. 2017;58:387–92. https://doi.org/10.2967/jnumed.116.181859.CrossRefPubMed

10.

Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery. 2013;153:526–34. https://doi.org/10.1016/j.surg.2012.10.007.CrossRefPubMed

11.

Imamura Y, Watanabe M, Nagai Y, et al. Lymphatic vessel invasion detected by the D2-40 monoclonal antibody is an independent prognostic factor in node-negative esophageal squamous cell carcinoma. J Surg Oncol. 2012;105:277–83. https://doi.org/10.1002/jso.22079.CrossRefPubMed

12.

Saad RS, Lindner JL, Liu Y, Silverman JF. Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma. Am J Clin Pathol. 2009;131:92–8. https://doi.org/10.1309/AJCPKWUQSIPVG90H.CrossRefPubMed

13.

Tong L, Yuan S, Feng F, Zhang H. Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus. 2012;25:72–80. https://doi.org/10.1111/j.1442-2050.2011.01211.x.CrossRefPubMed

14.

Ma W, Wang K, Yang S, et al. Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7:2361–71.PubMedPubMedCentral

15.

Inoue A, Moriya H, Katada N, et al. Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis. Pathol Int. 2008;58:611–9. https://doi.org/10.1111/j.1440-1827.2008.02279.x.CrossRefPubMed

16.

Kumagai Y, Tachikawa T, Higashi M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis at the early stage of esophageal squamous cell carcinoma progression. Dis Esophagus. 2018;31. https://doi.org/10.1093/dote/doy011.

17.

Mori D, Yamasaki F, Shibaki M, Tokunaga O. Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma. Mod Pathol. 2007;20:694–700. https://doi.org/10.1038/modpathol.3800786.CrossRefPubMed

18.

Lund AW, Wagner M, Fankhauser M, et al. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016;126:3389–402. https://doi.org/10.1172/JCI79434.CrossRefPubMedPubMedCentral

19.

Leslie H, Sobin MKG, Wittekind C. TNM classification of malignant tumors. 7th ed. Wiley-Blackwell, Oxford, NJ, USA, 2010.

20.

Yamashita K, Makino T, Yamasaki M, et al. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer. Dis Esophagus. 2017;30:1–8. https://doi.org/10.1093/dote/dox096.CrossRefPubMed

21.

Miyata H, Yamasaki M, Miyazaki Y, et al. Clinical importance of supraclavicular lymph node metastasis after neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg. 2015;262:280–5. https://doi.org/10.1097/sla.0000000000000933.CrossRefPubMed

22.

Makino T, Yamasaki M, Miyata H, et al. Solitary lymph node recurrence of esophageal squamous cell carcinoma: surgical failure or systemic disease? Ann Surg Oncol. 2016;23:2087–93. https://doi.org/10.1245/s10434-015-5086-y.CrossRefPubMed

23.

Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: the past, the present, and the future. Ann Gastroenterol Surg. 2017;1:5–10. https://doi.org/10.1002/ags3.12008.CrossRefPubMedPubMedCentral

24.

Urakawa S, Makino T, Yamasaki M, et al. Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer. Ann Surg. 2019. https://doi.org/10.1097/SLA.0000000000003445.CrossRefPubMed

25.

Makino T, Yamasaki M, Tanaka K, et al. The impact of prophylactic administration of a neutrophil elastase inhibitor on the postoperative course in older patients undergoing esophagectomy for esophageal cancer: a propensity score-matched analysis. Esophagus. 2017;14:241–8. https://doi.org/10.1007/s10388-017-0571-y.CrossRef

26.

Hagi T, Makino T, Yamasaki M, et al. Dysphagia score as a predictor of adverse events due to triplet chemotherapy and oncological outcomes in 434 consecutive patients with esophageal cancer. Ann Surg Oncol. 2019;26:4754–64. https://doi.org/10.1245/s10434-019-07744-7.CrossRefPubMed

27.

Makino T, Yamasaki M, Miyazaki Y, et al. Short- and long-term outcomes of larynx-preserving surgery for cervical esophageal cancer: analysis of 100 consecutive cases. Ann Surg Oncol. 2016;23(Suppl 5):858–65. https://doi.org/10.1245/s10434-016-5511-x.CrossRefPubMed

28.

Makino T, Yamasaki M, Miyazaki Y, et al. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Dis Esophagus. 2018;31. https://doi.org/10.1093/dote/dox130.

29.

Diseases JSfE. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 11th ed. Kanehara Shuppan, Tokyo, Japan, 2015.

30.

Hashimoto T, Makino T, Yamasaki M, et al. The pattern of residual tumor after neoadjuvant chemotherapy for locally advanced esophageal cancer and its clinical significance. Ann Surg. 2020;271:875–84. https://doi.org/10.1097/SLA.0000000000003129.CrossRefPubMed

31.

Makino T, Yamasaki M, Tanaka K, et al. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery. 2017;162:836–45. https://doi.org/10.1016/j.surg.2017.06.007.CrossRefPubMed

32.

Makino T, Miyata H, Yamasaki M, et al. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma. Surgery. 2010;148:908–18. https://doi.org/10.1016/j.surg.2010.02.016.CrossRefPubMed

33.

Makino T, Doki Y, Miyata H, et al. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery. 2008;144:793–802. https://doi.org/10.1016/j.surg.2008.06.026.CrossRefPubMed

34.

Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55:414–22. https://doi.org/10.2967/jnumed.113.129858.CrossRefPubMed

35.

Zhao YC, Ni XJ, Li Y, et al. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. World J Surg Oncol. 2012;10:165. https://doi.org/10.1186/1477-7819-10-165.CrossRefPubMedPubMedCentral

36.

Niemiec JA, Adamczyk A, Ambicka A, et al. Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer. Am J Transl Res. 2017;9:1435–47.PubMedPubMedCentral

37.

Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78. https://doi.org/10.2967/jnumed.110.082404.CrossRefPubMedPubMedCentral

Titel: Peritumoral Lymphatic Vessels Associated with Resistance to Neoadjuvant Chemotherapy and Unfavorable Survival in Esophageal Cancer
verfasst von: Takeo Hara, MD, PhD
Tomoki Makino, MD, PhD
Makoto Yamasaki, MD, PhD
Koji Tanaka, MD, PhD
Kotaro Yamashita, MD, PhD
Yuya Nogi, MD
Takuro Saito, MD, PhD
Tsuyoshi Takahashi, MD, PhD
Yukinori Kurokawa, MD, PhD
Mitsuaki Tatsumi, MD, PhD
Kiyokazu Nakajima, MD, PhD
Eiichi Morii, MD, PhD
Hidetoshi Eguchi, MD, PhD
Yuichiro Doki, MD, PhD
Publikationsdatum: 23.04.2020
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 10/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08474-x

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

ASO Author Reflections: Utility of New 99mTc-MIBI Scintigraphy Before Reoperating Patients with Persistent Sporadic Primary Hyperparathyroidism: Results of a Retrospective Multicenter Study

ASO Author Reflections: Lung Adenocarcinoma with Accidental Invisible Pleural Dissemination Lesions: Wait-and-See Strategy for Tumors with Indolent Biologic Characteristics

Long-Term Outcomes of Pulmonary Metastasectomy for Uterine Malignancies: A Multi-institutional Study in the Current Era

ASO Author Reflections: A Nomogram to Predict Recurrence after Curative-Intent Resection for Neuroendocrine Liver Metastasis

Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis

MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“